K2M Group Holdings Inc (KTWO) was Downgraded by Northland Capital to ” Market Perform”. Earlier the firm had a rating of “Outperform ” on the company shares. Northland Capital advised their investors in a research report released on May 3, 2016.
Many Wall Street Analysts have commented on K2M Group Holdings Inc. K2M Group Holdings Inc was Initiated by JMP Securities to “Mkt Outperform” on Apr 8, 2016. Shares were Reiterated by Needham on Mar 4, 2016 to “Buy” and Lowered the Price Target to $ 21 from a previous price target of $25 .
On the company’s financial health, K2M Group Holdings Inc reported $-0.25 EPS for the quarter, missing the analyst consensus estimate by $ -0.02 based on the information available during the earnings call on May 2, 2016. Analyst had a consensus of $-0.23. The company had revenue of $56.30 million for the quarter, compared to analysts expectations of $55.97 million. The company’s revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.37 EPS.
K2M Group Holdings Inc closed down -0.39 points or -2.40% at $15.87 with 3,28,560 shares getting traded on Monday. Post opening the session at $16.41, the shares hit an intraday low of $15.71 and an intraday high of $16.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Mar 7, 2016, Carlos A Ferrer (director) purchased 38,942 shares at $12.84 per share price. According to the SEC, on Nov 13, 2015, Gregory S Cole (Chief Financial Officer) sold 41,574 shares at $19.69 per share price. On Jun 24, 2015, John Philip Md Kostuik (Chief Medical Officer) sold 24,337 shares at $24.84 per share price, according to the Form-4 filing with the securities and exchange commission.
K2M Group Holdings Inc. (KTWO) is a global medical device company focused on designing developing and commercializing spine technologies and techniques. The Company’s spine products are used by spine surgeons to treat spinal pathologies such as deformity (primarily scoliosis) trauma and tumor. The Company is engaged in the design development and commercialization of a number of minimally invasive spine (MIS) products and products for patients suffering from degenerative spinal conditions. The Company’s products consist of implants disposables and instruments which are marketed and sold primarily to hospitals for use by spine surgeons. The Company’s technologies include MESA Rail 4D Deformity Cricket CAPRI SERENGETI RAVINE EVEREST and tifix. The Company offers products-based on its technologies for complex spine minimally invasive spine and degenerative spine. The Company is engaged in product development activities for the spine and MIS markets.